| Literature DB >> 33623790 |
Wenbin Wang1,2,3,4, Shuanhu Wang5, A Man Xu4, Xiao Yuan4, Liguo Huang4, Jun Li1,3.
Abstract
Gastric cancer is one of the most prevalent human cancers with poor prognosis. Trastuzumab is a well-used targeted drug for gastric cancer with HER2 amplification. Trastuzumab resistance restrains the clinical use of trastuzumab. In this study, we reported human Gse1 coiled-coil protein (GSE1) promoted trastuzumab resistance in HER2-positive gastric cancer cells. Acquired trastuzumab-resistant gastric cancer cells overexpressed GSE1, and depletion of GSE1 decreased the trastuzumab resistance of trastuzumab-resistant gastric cancer cells. BCL-2 was a downstream gene positively regulated by GSE1 and also performed promoting the role of trastuzumab resistance in HER2-positive gastric cancer cells. A high level of GSE1 was associated with a high risk of tumor lymph node metastasis and higher clinical stage in HER2-positive gastric cancer patients. GSE1 was a potential target that could be used for HER2-positive gastric cancer therapy.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33623790 PMCID： PMC7875631 DOI： 10.1155/2021/8834923
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411